Clinical characteristics, treatment, and survival of thrombocytopenia induced by T-DM1 in early HER2-positive breast cancer

Clinical characteristics, treatment, and survival of thrombocytopenia induced by T-DM1 in early HER2-positive breast cancer

BackgroundTrastuzumab emtansine (T-DM1) is widely used for treating both early and advanced HER2-positive breast cancer in China. Thrombocytopenia represents a major adverse event associated with T-DM1 during anti-tumor therapy. Therefore, further exploration is needed to predict and mitigate T-DM1-...

Full description

Saved in:
Bibliographic Details
Main Authors: Fang Wang, Xiaosan Zhang, Xiuchun Chen, Lu Zhang, Zhenzhen Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Oncology
Subjects:
HER2-positive breast cancer
T-DM1
thrombocytopenia
safety
effectiveness
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1592440/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items